Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
- PMID: 38944565
- DOI: 10.1016/j.cllc.2024.06.003
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
Keywords: C797S; EGFR; Gefitinib; Osimertinib resistance; Rechallenge.
Conflict of interest statement
Disclosure Dr Russo has received advisory board, consultancy or speaker bureau honoraria from AstraZeneca, MSD, Novartis, Pfizer, BMS, Roche, Takeda, and Amgen outside the submitted work; compensated activity for editorial projects from AstraZeneca, MSD, Novartis, and Roche outside the submitted work. The other authors declare no conflicts of interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
